For the quarter ending 2026-01-31, ANIX had $303K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|
| Research and development expenses | 1,102 | - | - |
| General and administrative expenses | 1,614 | - | - |
| Total operating costs and expenses | 2,716 | - | - |
| Loss from operations | -2,716 | - | - |
| Common stock issued to consultants | - | - | 0 |
| Interest income | 131 | - | - |
| Net loss | -2,585 | -2,722 | -8,306 |
| Stock option compensation to employees and directors | 768 | 859 | 2,822 |
| Stock options issued to consultants | 28 | 52 | 77 |
| Amortization of operating lease right-of-use asset | 10 | 9 | 27 |
| Amortization of discount on held-to-maturity securities | - | 50 | 93 |
| Receivables | - | 0 | -173 |
| Amortization of discount on held-to-maturity securities | -47 | - | - |
| Prepaid expenses and other current assets | 135 | -707 | 155 |
| Accounts payable | -17 | -111 | -249 |
| Accrued expenses | -715 | 10 | -195 |
| Operating lease liability | -11 | -9 | -19 |
| Net cash used in operating activities | -2,610 | -1,255 | -5,918 |
| Disbursements to acquire short-term investments | 12,532 | 7,660 | 36,700 |
| Proceeds from maturities of short-term investments | 13,760 | 8,314 | 40,912 |
| Net cash provided by investing activities | 1,228 | 654 | 4,212 |
| Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of 183 and 168, for the years ended october 31, 2025 and 2024, respectively | - | 454 | 1,924 |
| Proceeds from sale of common stock pursuant to employee stock purchase plan | - | 3 | 4 |
| Net proceeds (expenses) from an at-the-market offering | 1,625 | - | - |
| Net (costs) proceeds from exercise of stock options | - | -105 | - |
| Proceeds from exercise of stock options | 58 | - | 2 |
| Net cash provided by (used in) financing activities | 1,685 | 350 | 1,930 |
| Net increase (decrease) in cash and cash equivalents | 303 | -251 | 224 |
| Cash and cash equivalents at beginning of period | 1,244 | 1,271 | - |
| Cash and cash equivalents at end of period | 1,547 | 1,244 | - |
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)